^
Association details:
| Biomarker: | EGFRvIII mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | TAS2940 (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TAS2940, a Novel Brain-Penetrable Pan-ERBB Inhibitor, for Tumors with HER2 and EGFR Aberrations
Published date:
10/25/2022
Excerpt:
TAS2940 also inhibited tumor growth in xenograft mouse models with ERBB aberrations: HER2 amplification, HER2/EGFR exon 20 insertions, and EGFR vIII mutation. TAS2940 was effective in the intracranial xenograft models of HER2/EGFR cancers and improved the survival of these mice. TAS2940 has promising therapeutic effects in preclinical study against cancers harboring HER2/EGFR mutations, especially metastatic and primary brain tumors.
DOI:
10.1111/cas.15617
